Amendments to the Claims:

Claims 1-32 (cancelled).

Claim 33 (currently amended): A method for treating cancer in a mammal, wherein the cancer is of a type that is caused by a genetic defect in a gene that mediates homologous recombination and is selected from the group consisting of cancer of the: breast, lung, colon, pancreas, stomach, ovary, cervix, breast, prostate, bone, brain, and skin, the gene that mediates homologous recombination being selected from the group consisting of: XRCC1, CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51, RAD51C, RAD51D, DMC1, XRCCR, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NB51, WRN, BLM KU70, KU80, ATM, ATR CHK1, CHK2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9 and combinations thereof, the method comprising:

selecting the mammal having said genetic defect; and

administering to the mammal a compound selected from the group consisting of a compound of the formula I, formula II and formula III:



I



II



III

or a pharmaceutically acceptable salt thereof.

Claim 34 (previously presented): The method according to Claim 33, wherein the compound is the compound of the formula **I**.

Claim 35 (previously presented): The method according to Claim 34, wherein the compound of the formula I is in the form of a phosphate salt.

Claim 36 (canceled).

Claim 37 (previously presented): The method of Claim 36, wherein the cancer is breast cancer.

Claim 38 (previously presented): The method of Claim 33, wherein the genetic defect is the absence of a gene encoding a protein involved in homologous recombination.

Claim 39 (previously presented): The method of Claim 33, wherein the genetic defect is in the expression of a gene encoding a protein involved in homologous recombination.

Claim 40 (canceled).

Claim 41 (previously presented): The method of Claim 33, wherein the gene that mediates homologous recombination is a tumor suppressor gene.

Claim 42 (previously presented): The method of Claim 41, wherein the tumor suppressor gene is BRCA1 and/or BRCA2.

Claim 43 (currently amended): A method for inducing apoptosis of cells defective in a gene that mediates homologous recombination, the cells being cancer cells selected from the group consisting of cancer cells of the: breast, lung, colon, pancreas, stomach, ovary, cervix, breast, prostate, bone, brain, and skin, the gene that mediates homologous recombination being selected from the group consisting of: XRCC1, CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51β, RAD51C, RAD51D, DMC1, XRCCR, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NB51, WRN, BLM KU70, KU80, ATM, ATR CHK1, CHK2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9 and combinations thereof, the method comprising:

selecting the cancer cells having said genetic defect; and

administering to the cancer cells a compound selected from the group consisting of a compound of the formula I, formula II and formula III:



I



II



III

or a pharmaceutically acceptable salt thereof.

Claim 44 (previously presented): The method according to Claim 43, wherein the compound is the compound of the formula I.

Claim 45 (previously presented): The method according to Claim 44, wherein the compound of the formula I is in the form of a phosphate salt.

Claim 46 (canceled).

Claim 47 (previously presented): The method of Claim 43, wherein the genetic defect of the cells is the absence of a gene encoding a protein involved in homologous recombination.

Claim 48 (previously presented): The method of Claim 43, wherein the genetic defect of the cells is in the expression of a gene encoding a protein involved in homologous recombination.

Claim 49 (canceled).

Claim 50 (previously presented): The method of Claim 43, wherein the gene that mediates homologous recombination is a tumor suppressor gene.

Claim 51 (previously presented): The method of Claim 50, wherein the tumor suppressor gene is BRCA1 and/or BRCA2 and the cancer cells are selected from the group consisting of cancer cells of the: lung, colon, pancreas, stomach, ovary, cervix, breast, prostate, bone, brain, and skin.